We develop innovative biopharmaceuticals using immunomodulatory properties of stem cells. The first Bioceltix drugs will soon reach veterinary clinics all over the world.
As we develop stem cell-based biopharmaceuticals for veterinary use in Bioceltix, our greatest concern is to ensure patient safety and treatment efficacy. We are now conducting developmental research on three biological drugs based on mesenchymal stem cells (MSCs). Two of them – BCX-CM-J and BCX-CM-AD – are currently in the clinical development phase. The purpose of the conducted studies is to confirm the safety and efficacy of our candidate drugs. Third of the candidate drugs, BCX-EM, used in the treatment of arthritis in horses, is in the final phase of manufacturing process optimisation according to the pharmaceutical standards.
In the development of innovative biopharmaceuticals, we want to harness the therapeutic potential of mesenchymal stem cells, using MSCs as an active pharmaceutical ingredient.
A stem-cell based biological drug intended for the treatment of degenerative joint lesions in dogs. Its active pharmaceutical ingredient is a suspension of allogeneic mesenchymal stem cells.
Check product
A biological drug candidate based on allogeneic stem cells, used in intravenous injection. Intended for the treatment of atopic dermatitis in dogs.
Check product
A biological drug candidate based on allogeneic mesenchymal stem cells, used in intra-articular injection. It is intended for the treatment of arthritis in horses.
Check product
